JPRN-UMIN000023446CompletedPhase 2
A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial) - A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)
ational Cancer Center0 sites30 target enrollmentStarted: August 2, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 79years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Active double cancer; synchronous or metachronous within 5years. Patients with carcinoma in situ are eligible 2)Infections requiring systemic therapy 3)Fever of >=38 degrees Celsius at the time of registration 4)Grade >=2 adverse reactions caused by prior therapy except any grade of alopecia and grade 2 peripheral neurotoxicity 5)Pregnant or breast-feeding women,or women suspected of being pregnant 6)Mental disease interfering taking part in the trial 7)Taking continuous systemic steroids and/or other immunosuppressive drugs(orally or intravenously) 8)HIV antibody positive 9)Interstitial pneumonia and/or pulmonary fibrosis and/or severe pulmonary emphysema diagnosed by chest CT imaging 10)History of any of the followings; unstable angina and transient ischemic attacks within 6 months before registration, or heart attack,pulmonary embolism,deep vein thrombosis,brain bleeding,cerebral infarction and arterial thromboembolism
Investigators
Similar Trials
Completed
Phase 2
Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial (NCCH1508,REMORA trial)Thymic carcinomaJPRN-UMIN000026777ational Cancer Center42
Completed
Phase 2
Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinomaThymic carcinomaJPRN-jRCT2091220285oboru YamamotoDepartment of Experimental Therapeutics, National Cancer Center Hospital42
Not yet recruiting
Unknown
Multicenter phase II trial of lenvatinib in patients with unresectable or metastatic hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumabKCT0008607Asan Medical Center50
Active, not recruiting
Phase 1
Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tractEUCTR2015-000693-35-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI26
Active, not recruiting
Phase 2
A phase II study of lenvatinib (E7080/MK-7902) in combination with carboplatin pemetrexed and pembrolizumab (MK-3475) for patients with pretreated advanced non-squamous non-small cell lung cancer harboring EGFR mutationsAdvanced non-squamous non-small cell lung cancer harboring EGFR mutationsJPRN-jRCT2031220147Takahashi Kazuhisa30